Lubiprostone
Catalog #:
AG0011Shipping advice:
Suitable for Express Delivery only (1-day). International shipping rate please contact us for details
| AG0011-5mg/15 ul DMSO | USD250.0 |
| AG0011-10mg/30 ul DMSO | USD450.0 |
Synonyms: Lubiprostone, (Amitiza), RU-0211, SPI-0211
IUPAC Name:
7-[(1R,3R,6R,7R)-3-(1,1-difluoropentyl)-3-hydroxy-8-oxo-2-oxabicyclo[4.3.0]non-7-yl]heptanoic acidFunctional Activity:
Lubiprostone is a bicyclic fatty acid derived from prostaglandin E1 that acts by specifically activating ClC-2 chloride channels on the apical aspect of gastrointestinal epithelial cells, producing a chloride-rich fluid secretion. These secretions soften the stool, increase motility, and promote spontaneous bowel movements (SBM).Technical Data:
M.Wt: 390.46
Formula: C20H32F2O5
Solubility: Unknown
Purity: >99%
Storage: Dessicate at -20 °C for 2 years
CAS No.: 136790-76-6
Related Products by Target:
Solubility: Unknown
Purity: >99%
Storage: Dessicate at -20 °C for 2 years
CAS No.: 136790-76-6
Related Products by Target:
Storage: Dessicate at -20 °C for 2 years
CAS No.: 136790-76-6
Related Products by Target:
Related Products by Target:
References for Lubiprostone:
1. Mizumori, M., Akiba, Y., and Kaunitz, J. D. Lubiprostone stimulates duodenal bicarbonate secretion in rats. Dig Dis Sci, 54: 2063-2069, 2009.
2. Hooks, S. B., 3rd, Rutland, T. J., and Di Palma, J. A. Lubiprostone neither decreases gastric and small-bowel transit time nor improves visualization of small bowel for capsule endoscopy: a double-blind, placebo-controlled study. Gastrointest Endosc, 70: 942-946, 2009.
3. Carter, N. J. and Scott, L. J. Lubiprostone: in constipation-predominant irritable bowel syndrome. Drugs, 69: 1229-1237, 2009.
4. Bijvelds, M. J., Bot, A. G., Escher, J. C., and De Jonge, H. R. Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology, 137: 976-985, 2009.
5. Crowell, M. D. Lubiprostone: trials and tribulations. Nat Rev Gastroenterol Hepatol, 6: 259-260, 2009.
6. Kapoor, S. Lubiprostone: clinical applications beyond constipation. World J Gastroenterol, 15: 1147, 2009.
7. Lacy, B. E. and Chey, W. D. Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. Expert Opin Pharmacother, 10: 143-152, 2009.
8. Joo, N. S., Wine, J. J., and Cuthbert, A. W. Lubiprostone stimulates secretion from tracheal submucosal glands of sheep, pigs, and humans. Am J Physiol Lung Cell Mol Physiol, 296: L811-824, 2009.
9. Drinka, P. Lubiprostone to prevent fecal impaction. J Am Med Dir Assoc, 10: 211, 2009.
10. Fei, G., Wang, Y. Z., Liu, S., Hu, H. Z., Wang, G. D., Qu, M. H., Wang, X. Y., Xia, Y., Sun, X., Bohn, L. M., Cooke, H. J., and Wood, J. D. Stimulation of mucosal secretion by lubiprostone (SPI-0211) in guinea pig small intestine and colon. Am J Physiol Gastrointest Liver Physiol, 296: G823-832, 2009.
11. Owen, R. T. Lubiprostone--a novel treatment for irritable bowel syndrome with constipation. Drugs Today (Barc), 44: 645-652, 2008.
12. Tuteja, A. K. and Rao, S. S. Lubiprostone for constipation and irritable bowel syndrome with constipation. Expert Rev Gastroenterol Hepatol, 2: 727-733, 2008.
